Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386030165> ?p ?o ?g. }
- W4386030165 endingPage "2098" @default.
- W4386030165 startingPage "2098" @default.
- W4386030165 abstract "Immunotherapy has recently been incorporated into the spectrum of biliary tract cancer (BTC) treatment. The identification of predictive response biomarkers is essential in order to identify those patients who may benefit most from this novel treatment option. Here, we propose a systematic literature review and a meta-analysis of PD-1, PD-L1, and other immune-related biomarker expression levels in patients with BTC.Prisma guidelines were followed for this systematic review and meta-analysis. Eligible studies were searched on PubMed. Studies published between 2017 and 2022, reporting data on PD-1/PD-L1 expression and other immune-related biomarkers in patients with BTC, were considered eligible.A total of 61 eligible studies were identified. Despite the great heterogeneity between 39 studies reporting data on PD-L1 expression, we found a mean PD-L1 expression percentage (by choosing the lowest cut-off per study) of 25.6% (95% CI 21.0 to 30.3) in BTCs. The mean expression percentages of PD-L1 were 27.3%, 21.3%, and 27.4% in intrahepatic cholangiocarcinomas (iCCAs-15 studies), perihilar-distal CCAs (p/dCCAs-7 studies), and gallbladder cancer (GBC-5 studies), respectively. Furthermore, 4.6% (95% CI 2.38 to 6.97) and 2.5% (95% CI 1.75 to 3.34) of BTCs could be classified as TMB-H and MSI/MMRd tumors, respectively.From our analysis, PD-L1 expression was found to occur approximately in 26% of BTC patients, with minimal differences based on anatomical location. TMB-H and MSI molecular phenotypes occurred less frequently. We still lack a reliable biomarker, especially in patients with mismatch-proficient tumors, and we must need to make an effort to conceive new prospective biomarker discovery studies." @default.
- W4386030165 created "2023-08-22" @default.
- W4386030165 creator A5015809186 @default.
- W4386030165 creator A5035435158 @default.
- W4386030165 creator A5047404111 @default.
- W4386030165 creator A5050790248 @default.
- W4386030165 creator A5066637157 @default.
- W4386030165 creator A5078840896 @default.
- W4386030165 creator A5084083958 @default.
- W4386030165 date "2023-08-19" @default.
- W4386030165 modified "2023-10-02" @default.
- W4386030165 title "Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis" @default.
- W4386030165 cites W2090043182 @default.
- W4386030165 cites W2339631364 @default.
- W4386030165 cites W2342685632 @default.
- W4386030165 cites W2554089088 @default.
- W4386030165 cites W2556195366 @default.
- W4386030165 cites W2585601100 @default.
- W4386030165 cites W2587048937 @default.
- W4386030165 cites W2607173021 @default.
- W4386030165 cites W2609802199 @default.
- W4386030165 cites W2724543993 @default.
- W4386030165 cites W2732060629 @default.
- W4386030165 cites W2763584377 @default.
- W4386030165 cites W2796789662 @default.
- W4386030165 cites W2797443945 @default.
- W4386030165 cites W2799610897 @default.
- W4386030165 cites W2802975351 @default.
- W4386030165 cites W2806413170 @default.
- W4386030165 cites W2883150683 @default.
- W4386030165 cites W2893903398 @default.
- W4386030165 cites W2894518105 @default.
- W4386030165 cites W2897815318 @default.
- W4386030165 cites W2898899606 @default.
- W4386030165 cites W2912073938 @default.
- W4386030165 cites W2914163382 @default.
- W4386030165 cites W2920849174 @default.
- W4386030165 cites W2940160729 @default.
- W4386030165 cites W2944614981 @default.
- W4386030165 cites W2944675676 @default.
- W4386030165 cites W2945815647 @default.
- W4386030165 cites W2946053006 @default.
- W4386030165 cites W2947375816 @default.
- W4386030165 cites W2962238349 @default.
- W4386030165 cites W2963941603 @default.
- W4386030165 cites W2968593600 @default.
- W4386030165 cites W2968650854 @default.
- W4386030165 cites W2973131636 @default.
- W4386030165 cites W2979343554 @default.
- W4386030165 cites W2982023685 @default.
- W4386030165 cites W2984359187 @default.
- W4386030165 cites W2995596733 @default.
- W4386030165 cites W2996284088 @default.
- W4386030165 cites W2997667667 @default.
- W4386030165 cites W2999115341 @default.
- W4386030165 cites W3005146678 @default.
- W4386030165 cites W3005605254 @default.
- W4386030165 cites W3010993117 @default.
- W4386030165 cites W3032356763 @default.
- W4386030165 cites W3037699942 @default.
- W4386030165 cites W3040375254 @default.
- W4386030165 cites W3042957895 @default.
- W4386030165 cites W3044419735 @default.
- W4386030165 cites W3048388428 @default.
- W4386030165 cites W3083986479 @default.
- W4386030165 cites W3084486301 @default.
- W4386030165 cites W3092842585 @default.
- W4386030165 cites W3099439074 @default.
- W4386030165 cites W3107426578 @default.
- W4386030165 cites W3109637979 @default.
- W4386030165 cites W3111350541 @default.
- W4386030165 cites W3115710363 @default.
- W4386030165 cites W3119460081 @default.
- W4386030165 cites W3131681136 @default.
- W4386030165 cites W3134430032 @default.
- W4386030165 cites W3135403528 @default.
- W4386030165 cites W3135677444 @default.
- W4386030165 cites W3137671123 @default.
- W4386030165 cites W3138150836 @default.
- W4386030165 cites W3142881787 @default.
- W4386030165 cites W3155417375 @default.
- W4386030165 cites W3156802528 @default.
- W4386030165 cites W3157352963 @default.
- W4386030165 cites W3158306799 @default.
- W4386030165 cites W3161294326 @default.
- W4386030165 cites W3165425277 @default.
- W4386030165 cites W3165958373 @default.
- W4386030165 cites W3173308357 @default.
- W4386030165 cites W3186633100 @default.
- W4386030165 cites W3197362918 @default.
- W4386030165 cites W3200481426 @default.
- W4386030165 cites W3206098810 @default.
- W4386030165 cites W3208128412 @default.
- W4386030165 cites W3209761134 @default.
- W4386030165 cites W4200280770 @default.
- W4386030165 cites W4205712453 @default.
- W4386030165 cites W4211025847 @default.
- W4386030165 cites W4211133027 @default.